NorthWest Biotherapeutics Inc (NWBO)

[Gus1212]

Merck (NYSE:MRK) announced on April 28 that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for a new treatment schedule for its marquee cancer drug, Keytruda. For context, Keytruda posted $11.1 billion in sales last year. Its closest competitor, Opdivo from Bristol Myers Squibb (NYSE:BMY), generated $7.2 billion in 2019 sales. The stakes are high for these blockbuster drugs, which have changed the cancer treatment landscape in recent years.

Come on Merck - we can steal that 7.2 billion market from Bristol Myers
Together !!!!!!!


Duffy Let Roll !!


Don't Make Me Leak